JPH0513696B2 - - Google Patents

Info

Publication number: JPH0513696B2
Authority: JP; Japan
Prior art keywords: adsorbent; carrier; blood; antibodies; acid
Prior art date: 1983-10-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP58196145A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6090039A (ja

Inventor

Morimasa Kaneko

Naokuni Yamawaki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Asahi Chemical Industry Co Ltd

Original Assignee

Asahi Chemical Industry Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-10-21

Filing date

1983-10-21

Publication date

1993-02-23

1983-10-21 Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd

1983-10-21 Priority to JP58196145A priority Critical patent/JPS6090039A/ja

1985-05-21 Publication of JPS6090039A publication Critical patent/JPS6090039A/ja

1993-02-23 Publication of JPH0513696B2 publication Critical patent/JPH0513696B2/ja

Status Granted legal-status Critical Current

Links

239000003463 adsorbent Substances 0.000 claims description 48
239000000126 substance Substances 0.000 claims description 28
210000004369 blood Anatomy 0.000 claims description 25
239000008280 blood Substances 0.000 claims description 24
229920000447 polyanionic polymer Polymers 0.000 claims description 21
238000000746 purification Methods 0.000 claims description 9
150000002894 organic compounds Chemical class 0.000 claims description 3
238000000034 method Methods 0.000 description 34
238000001179 sorption measurement Methods 0.000 description 24
-1 particulate Substances 0.000 description 20
230000003211 malignant effect Effects 0.000 description 17
210000001124 body fluid Anatomy 0.000 description 16
239000010839 body fluid Substances 0.000 description 16
239000013110 organic ligand Substances 0.000 description 15
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 14
229920000642 polymer Polymers 0.000 description 14
210000004027 cell Anatomy 0.000 description 13
210000001772 blood platelet Anatomy 0.000 description 12
238000011282 treatment Methods 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
239000003446 ligand Substances 0.000 description 10
239000000969 carrier Substances 0.000 description 9
235000018102 proteins Nutrition 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
229920001577 copolymer Polymers 0.000 description 8
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
229960005190 phenylalanine Drugs 0.000 description 6
239000004593 Epoxy Substances 0.000 description 5
230000023555 blood coagulation Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
238000010559 graft polymerization reaction Methods 0.000 description 5
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
239000000243 solution Substances 0.000 description 5
201000000596 systemic lupus erythematosus Diseases 0.000 description 5
238000012360 testing method Methods 0.000 description 5
229920002554 vinyl polymer Polymers 0.000 description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000000499 gel Substances 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
239000010410 layer Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000178 monomer Substances 0.000 description 4
238000012856 packing Methods 0.000 description 4
229920005989 resin Polymers 0.000 description 4
239000011347 resin Substances 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
102000006395 Globulins Human genes 0.000 description 3
108010044091 Globulins Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
208000019423 liver disease Diseases 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
206010039073 rheumatoid arthritis Diseases 0.000 description 3
229920001059 synthetic polymer Polymers 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 2
JLIDVCMBCGBIEY-UHFFFAOYSA-N 1-penten-3-one Chemical compound CCC(=O)C=C JLIDVCMBCGBIEY-UHFFFAOYSA-N 0.000 description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
XFCMNSHQOZQILR-UHFFFAOYSA-N 2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOC(=O)C(C)=C XFCMNSHQOZQILR-UHFFFAOYSA-N 0.000 description 2
AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000000781 anti-lymphocytic effect Effects 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
125000003700 epoxy group Chemical group 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
201000008383 nephritis Diseases 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000004584 polyacrylic acid Substances 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
VZQZXAJWZUSYHU-TXPJSTSBSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-1-[(3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]hexan-1-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VZQZXAJWZUSYHU-TXPJSTSBSA-N 0.000 description 1
PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 description 1
JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical compound C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
MWZJGRDWJVHRDV-UHFFFAOYSA-N 1,4-bis(ethenoxy)butane Chemical compound C=COCCCCOC=C MWZJGRDWJVHRDV-UHFFFAOYSA-N 0.000 description 1
OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
SAMJGBVVQUEMGC-UHFFFAOYSA-N 1-ethenoxy-2-(2-ethenoxyethoxy)ethane Chemical compound C=COCCOCCOC=C SAMJGBVVQUEMGC-UHFFFAOYSA-N 0.000 description 1
BJELTSYBAHKXRW-UHFFFAOYSA-N 2,4,6-triallyloxy-1,3,5-triazine Chemical compound C=CCOC1=NC(OCC=C)=NC(OCC=C)=N1 BJELTSYBAHKXRW-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
BXAAQNFGSQKPDZ-UHFFFAOYSA-N 3-[1,2,2-tris(prop-2-enoxy)ethoxy]prop-1-ene Chemical compound C=CCOC(OCC=C)C(OCC=C)OCC=C BXAAQNFGSQKPDZ-UHFFFAOYSA-N 0.000 description 1
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
239000004925 Acrylic resin Substances 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000247812 Amorphophallus rivieri Species 0.000 description 1
235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
238000004438 BET method Methods 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
150000000703 Cerium Chemical class 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
208000014311 Cushing syndrome Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000001204 Hashimoto Disease Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
108010093096 Immobilized Enzymes Proteins 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
229920002752 Konjac Polymers 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
229920000877 Melamine resin Polymers 0.000 description 1
239000004640 Melamine resin Substances 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920002292 Nylon 6 Polymers 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000805 Polyaspartic acid Polymers 0.000 description 1
239000004693 Polybenzimidazole Substances 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
229920001807 Urea-formaldehyde Polymers 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229920001284 acidic polysaccharide Polymers 0.000 description 1
150000004805 acidic polysaccharides Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229920003180 amino resin Polymers 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical group 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
UXJHQBVRZUANLK-UHFFFAOYSA-N azanylidyne(dichloro)-$l^{5}-phosphane Chemical compound ClP(Cl)#N UXJHQBVRZUANLK-UHFFFAOYSA-N 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium(3+);trinitrate Chemical compound [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003508 chemical denaturation Methods 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
150000001923 cyclic compounds Chemical class 0.000 description 1
CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940052303 ethers for general anesthesia Drugs 0.000 description 1
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000002657 fibrous material Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000000585 glomerular basement membrane Anatomy 0.000 description 1
JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
239000012052 hydrophilic carrier Substances 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
230000036737 immune function Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
239000000252 konjac Substances 0.000 description 1
235000010485 konjac Nutrition 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000002523 lectin Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000113 methacrylic resin Substances 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
150000001451 organic peroxides Chemical class 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002270 phosphoric acid ester group Chemical group 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
108010064470 polyaspartate Proteins 0.000 description 1
229920002480 polybenzimidazole Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000010318 polygalacturonic acid Substances 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
229920000137 polyphosphoric acid Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
229920000909 polytetrahydrofuran Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920001289 polyvinyl ether Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
201000009395 primary hyperaldosteronism Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
206010048628 rheumatoid vasculitis Diseases 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
229920002050 silicone resin Polymers 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000010557 suspension polymerization reaction Methods 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229920001897 terpolymer Polymers 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
229920001567 vinyl ester resin Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Landscapes

External Artificial Organs (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

JP58196145A 1983-10-21 1983-10-21 血液浄化吸着体 Granted JPS6090039A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP58196145A JPS6090039A (ja)	1983-10-21	1983-10-21	血液浄化吸着体

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58196145A JPS6090039A (ja)	1983-10-21	1983-10-21	血液浄化吸着体

Publications (2)

Publication Number	Publication Date
JPS6090039A JPS6090039A (ja)	1985-05-21
JPH0513696B2 true JPH0513696B2 (fr)	1993-02-23

Family

ID=16352965

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58196145A Granted JPS6090039A (ja)	1983-10-21	1983-10-21	血液浄化吸着体

Country Status (1)

Country	Link
JP (1)	JPS6090039A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017536892A (ja) *	2014-11-26	2017-12-14	アントワーヌテュージィ	単独でまたはヒアルロン酸と組み合わせて、多血小板血漿（ｐｒｐ）または骨髄遠心分離液（ｃｅｎｔｒａｔｅ）（ｂｍｃ）を調製するための新しい規格化および医療デバイス

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0616842B2 (ja) *	1986-01-14	1994-03-09	鐘淵化学工業株式会社	活性化補体成分の吸着体
JPS62261368A (ja) *	1986-05-07	1987-11-13	東レ株式会社	アナフイラトキシン吸着材
JP2726662B2 (ja) *	1987-09-08	1998-03-11	鐘淵化学工業株式会社	吸着体およびそれを用いた除去装置
JPH0667472B2 (ja) *	1988-11-28	1994-08-31	鐘淵化学工業株式会社	血清アミロイドｐ蛋白用吸着体
JP2000262895A (ja) *	1999-03-17	2000-09-26	P Sharuma Chandora	免疫吸着剤マトリックスの製法および免疫吸着剤カラム
JP4578405B2 (ja) *	2003-05-08	2010-11-10	株式会社カネカ	全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器
WO2006049163A1 (fr) *	2004-11-05	2006-05-11	Kaneka Corporation	Matière produisant de la bradykinine servant à traiter un fluide corporel et permettant le traitement du sang total
US20070270523A1 (en) *	2004-11-05	2007-11-22	Kaneka Corporation	Method of Modifying Blood Contact Material and Blood Contact Material Inhibited from Activating Granulocyte
JP5374064B2 (ja) *	2008-03-31	2013-12-25	株式会社カネカ	血液接触材料の改質方法、及び補体活性化が抑制された血液接触材料

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5472294A (en) *	1977-11-18	1979-06-09	Hoechst Ag	Plastic material having improved adaptability with blood and method of making same
JPS5735978A (ja) *	1980-08-14	1982-02-26	Ishishiba Saabisu Kk	Mikakehijusenbetsuho
JPS57150433A (en) *	1981-03-12	1982-09-17	Kuraray Co Ltd	Carrier for immobilizing physiologically active material and selective adsorbent, selective electrode and analytical column using said carrier
JPS59192958A (ja) *	1982-10-15	1984-11-01	コミサリヤ・ア・レネルジ・アトミク	表面がグラフト化された粒子状支持体及びその製法並びに該支持体を含むアフイニテイクロマトグラフイ用吸着体及びその生物学的使用

1983
- 1983-10-21 JP JP58196145A patent/JPS6090039A/ja active Granted

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5472294A (en) *	1977-11-18	1979-06-09	Hoechst Ag	Plastic material having improved adaptability with blood and method of making same
JPS5735978A (ja) *	1980-08-14	1982-02-26	Ishishiba Saabisu Kk	Mikakehijusenbetsuho
JPS57150433A (en) *	1981-03-12	1982-09-17	Kuraray Co Ltd	Carrier for immobilizing physiologically active material and selective adsorbent, selective electrode and analytical column using said carrier
JPS59192958A (ja) *	1982-10-15	1984-11-01	コミサリヤ・ア・レネルジ・アトミク	表面がグラフト化された粒子状支持体及びその製法並びに該支持体を含むアフイニテイクロマトグラフイ用吸着体及びその生物学的使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017536892A (ja) *	2014-11-26	2017-12-14	アントワーヌテュージィ	単独でまたはヒアルロン酸と組み合わせて、多血小板血漿（ｐｒｐ）または骨髄遠心分離液（ｃｅｎｔｒａｔｅ）（ｂｍｃ）を調製するための新しい規格化および医療デバイス

Also Published As

Publication number	Publication date
JPS6090039A (ja)	1985-05-21

Publication	Publication Date	Title
GB2140424A (en)	1984-11-28	An adsorbent for absorbing thereonto an autoantibody and/or immune complexes from a body fluid
JPH0513696B2 (fr)	1993-02-23
JPS6353971B2 (fr)	1988-10-26
JP2543693B2 (ja)	1996-10-16	低比重リポ蛋白質の吸着材およびその製造方法
JPH0135670B2 (fr)	1989-07-26
JPH0323182B2 (fr)	1991-03-28
JPS59186558A (ja)	1984-10-23	リウマチ因子および／またはその免疫複合体の吸着材
JPS59186559A (ja)	1984-10-23	自己抗体および／または免疫複合体吸着材
JPS6087854A (ja)	1985-05-17	血液浄化吸着材
JPS6226073A (ja)	1987-02-04	直接血液潅流吸着方法およびその装置
JPS59169532A (ja)	1984-09-25	Ｃ反応性蛋白の吸着材
JPS5810055A (ja)	1983-01-20	免疫吸着器の製造方法
JPS5854959A (ja)	1983-04-01	免疫吸着装置の製造方法
JP2665526B2 (ja)	1997-10-22	β２−ミクログロブリンの吸着材
JPS6361024B2 (fr)	1988-11-28
JPS59189859A (ja)	1984-10-27	自己抗体、免疫複合体を吸着する材料
JPS6259976B2 (fr)	1987-12-14
JPS6259975B2 (fr)	1987-12-14
JPS60126165A (ja)	1985-07-05	血液適合性吸着材
JPH0429396B2 (fr)	1992-05-18
JPH0534024B2 (fr)	1993-05-21
JPS59186560A (ja)	1984-10-23	自己抗体、免疫複合体の吸着材
JPS6090038A (ja)	1985-05-21	血液適合性担体
JP2726662B2 (ja)	1998-03-11	吸着体およびそれを用いた除去装置
JPH0215222B2 (fr)	1990-04-11

JPH0513696B2 - - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=16352965

Family Applications (1)

Country Status (1)

Cited By (1)

Families Citing this family (9)

Citations (4)

Patent Citations (4)

Cited By (1)

Also Published As

Similar Documents